Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo
出版年份 2011 全文链接
标题
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo
作者
关键词
-
出版物
Blood Cancer Journal
Volume 1, Issue 9, Pages e34-e34
出版商
Springer Nature
发表日期
2011-09-02
DOI
10.1038/bcj.2011.30
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
- (2010) F. Chiarini et al. CANCER RESEARCH
- Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
- (2010) N. Chapuis et al. CLINICAL CANCER RESEARCH
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
- (2010) Shomit Sengupta et al. MOLECULAR CELL
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?
- (2010) Elias Jabbour et al. SEMINARS IN HEMATOLOGY
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
- (2009) F. Chiarini et al. CANCER RESEARCH
- Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
- (2009) G. Konstantinidou et al. CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells
- (2008) E. Weisberg et al. BLOOD
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- (2008) Michael G. Kharas et al. JOURNAL OF CLINICAL INVESTIGATION
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now